Turkey

Vista sencilla de ítem
dc.creatorCelik, Yusuf
dc.creatorSeiter, Andreas
dc.date2017-09-05T21:43:03Z
dc.date2017-09-05T21:43:03Z
dc.date2008
dc.date.accessioned2026-07-01T01:20:56Z
dc.descriptionPharmaceuticals are essential to achieve health outcomes, but are at the same time a major cost factor in every health system. From a patient perspective, access to pharmaceuticals is a proxy for the functioning of the health system. With increasing economic strength, patients become more demanding with regard to access to modern, sophisticated drugs and providers become more aggressive in marketing those drugs. This paper reflects the situation in the pharmaceutical sector in Turkey, identifies critical issues, and discusses policy options based on current trends and the overall policy objectives of the Turkish government. This paper is structured as follows: chapter one gives introduction; chapter two gives overall policy objectives in the pharmaceutical sector in Turkey; chapter three presents institutional and regulatory framework; chapter four presents reimbursement rules; chapter five focuses on governance issues in the pharmaceutical sector; chapter six gives market overview; chapter seven gives payment for pharmaceuticals in Turkey; chapter eight presents prescribing practices - rational use of medicines; and chapter nine gives conclusions and way forward.
dc.formatapplication/pdf
dc.formattext/plain
dc.identifierhttp://documents.worldbank.org/curated/en/389721468310466052/Turkey-Pharmaceutical-sector-analysis
dc.identifierhttps://hdl.handle.net/10986/28110
dc.identifierhttps://doi.org/10.1596/28110
dc.identifier.urihttp://hdl.handle.net/123456789/417276
dc.languageEnglish
dc.languageen_US
dc.publisherAnkara, World Bank
dc.rightsCC BY 3.0 IGO
dc.rightshttp://creativecommons.org/licenses/by/3.0/igo
dc.rightsWorld Bank
dc.subjectACCESS TO PHARMACEUTICALS
dc.subjectAGGRESSIVE
dc.subjectAGING
dc.subjectANTIBIOTICS
dc.subjectBASIC HEALTH CARE
dc.subjectBRAND
dc.subjectBRAND LOYALTY
dc.subjectBRAND NAME
dc.subjectBRAND NAME DRUGS
dc.subjectBRANDS
dc.subjectBRIBERY
dc.subjectBURDEN OF DISEASE
dc.subjectCHEMISTS
dc.subjectCHRONIC DISEASES
dc.subjectCLINICAL BENEFIT
dc.subjectCLINICAL PRACTICE
dc.subjectCLINICAL TRIALS
dc.subjectCOMPETITIVENESS
dc.subjectCONSUMER PROTECTION
dc.subjectCONTROLLED SUBSTANCES
dc.subjectCORRUPTION
dc.subjectCOST EFFECTIVENESS
dc.subjectCOST INCREASE
dc.subjectCOUNTERFEIT DRUGS
dc.subjectCRIME
dc.subjectDECISION MAKING
dc.subjectDIAGNOSING
dc.subjectDOCTORS
dc.subjectDRUG ADMINISTRATION
dc.subjectDRUG LAW
dc.subjectDRUG PRICES
dc.subjectEMPLOYMENT
dc.subjectESSENTIAL DRUGS
dc.subjectEXPENDITURE
dc.subjectEXPENDITURES
dc.subjectFRAUD
dc.subjectGENERIC DRUG COMPANIES
dc.subjectGENERIC DRUGS
dc.subjectGENERIC PRODUCTS
dc.subjectGENERIC SUBSTITUTION
dc.subjectGMP
dc.subjectGOOD MANUFACTURING PRACTICES
dc.subjectGREY MARKET
dc.subjectGROSS DOMESTIC PRODUCT
dc.subjectHEALTH CARE
dc.subjectHEALTH CARE EXPENDITURES
dc.subjectHEALTH CARE MANAGEMENT
dc.subjectHEALTH CARE SERVICES
dc.subjectHEALTH ECONOMICS
dc.subjectHEALTH EXPENDITURE
dc.subjectHEALTH EXPENDITURES
dc.subjectHEALTH INSURANCE
dc.subjectHEALTH INSURANCE COMPANIES
dc.subjectHEALTH INSURERS
dc.subjectHEALTH OUTCOMES
dc.subjectHEALTH POLICY
dc.subjectHEALTH SECTOR
dc.subjectHEALTH SERVICES
dc.subjectHEALTH STRATEGY
dc.subjectHEALTH SYSTEM
dc.subjectHEALTHCARE
dc.subjectHEALTHCARE SERVICES
dc.subjectHEROIN
dc.subjectHOSPITALS
dc.subjectILL PEOPLE
dc.subjectILLNESS
dc.subjectIMPORTED DRUGS
dc.subjectINCOME
dc.subjectINSURANCE COVERAGE
dc.subjectINTEGRATION
dc.subjectLAWS
dc.subjectLEUKEMIA
dc.subjectMARKET ACCESS
dc.subjectMARKET ENTRY
dc.subjectMARKET PRICE
dc.subjectMARKET RESEARCH
dc.subjectMARKET SHARE
dc.subjectMARKETING
dc.subjectMEDICAL SERVICES
dc.subjectMEDICINE
dc.subjectMEDICINES
dc.subjectMINISTRIES OF HEALTH
dc.subjectNARCOTICS
dc.subjectNURSES
dc.subjectNUTRITION
dc.subjectOUTPATIENT SERVICES
dc.subjectPACKAGING
dc.subjectPATENTS
dc.subjectPATIENT
dc.subjectPATIENT EDUCATION
dc.subjectPATIENTS
dc.subjectPAYMENT TERMS
dc.subjectPHARMACEUTICAL
dc.subjectPHARMACEUTICAL CONSUMPTION
dc.subjectPHARMACEUTICAL INDUSTRY
dc.subjectPHARMACEUTICAL INSPECTION
dc.subjectPHARMACEUTICAL MANUFACTURERS
dc.subjectPHARMACEUTICAL MANUFACTURING
dc.subjectPHARMACEUTICAL MARKETS
dc.subjectPHARMACEUTICAL POLICY
dc.subjectPHARMACEUTICAL PRICES
dc.subjectPHARMACEUTICAL PRICING
dc.subjectPHARMACEUTICAL PRODUCTS
dc.subjectPHARMACEUTICAL SECTOR
dc.subjectPHARMACEUTICALS
dc.subjectPHARMACIES
dc.subjectPHARMACISTS
dc.subjectPHARMACOECONOMIC ANALYSIS
dc.subjectPHARMACOECONOMIC STUDIES
dc.subjectPHARMACOECONOMICS
dc.subjectPHARMACOLOGISTS
dc.subjectPHARMACOLOGY
dc.subjectPHARMACY
dc.subjectPHYSICIAN
dc.subjectPHYSICIANS
dc.subjectPRESCRIPTIONS
dc.subjectPRICE ADJUSTMENTS
dc.subjectPRICE CHANGES
dc.subjectPRICE COMPARISON
dc.subjectPRICE COMPETITION
dc.subjectPRICE INCREASE
dc.subjectPRICE LEVELS
dc.subjectPRICE LIST
dc.subjectPRIMARY CARE
dc.subjectPRIVATE HEALTH INSURANCE
dc.subjectPRIVATE PHARMACIES
dc.subjectPROCUREMENT
dc.subjectPSYCHOTROPIC DRUGS
dc.subjectPUBLIC HEALTH
dc.subjectPUBLIC HOSPITALS
dc.subjectPURCHASING
dc.subjectQUALITY OF CARE
dc.subjectRATIONAL DRUG USE
dc.subjectRATIONAL USE OF DRUGS
dc.subjectREBATES
dc.subjectREGULATORY AUTHORITIES
dc.subjectRETAIL
dc.subjectRETAIL PHARMACIES
dc.subjectRETAIL PRICE
dc.subjectRETAIL PRICES
dc.subjectSALE
dc.subjectSALES
dc.subjectSTOCKS
dc.subjectSUBSTITUTE
dc.subjectSUPPLY CHAIN
dc.subjectSURGERY
dc.subjectTENDERING
dc.subjectTHERAPIES
dc.subjectTREATMENT GUIDELINES
dc.subjectTREATMENTS
dc.subjectVISITS
dc.subjectWAREHOUSE
dc.subjectWAREHOUSES
dc.subjectWHOLESALER
dc.subjectWHOLESALERS
dc.subjectWORKERS
dc.titleTurkey
dc.titlePharmaceutical Sector Analysis
dc.typeReport
dc.typeRapport
dc.typeInforme

Archivos

Colecciones

AgroKnow